Puma Biotechnology (NQ: PBYI )
8.370 USD -0.730 (-8.02%) Official Closing Price Updated: 7:26 PM EDT, Oct 30, 2020 Add to My Watchlist
Press releases about Puma Biotechnology
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 22, 2020
On November 5, 2020, Puma Biotechnology will issue its 3Q-2020 financial results after market close and host a conference call at 1:30 p.m. PST.
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer
October 05, 2020
Overall survival results from Puma Biotechnology's Phase III ExteNET trial were published online in Clinical Breast Cancer.
Puma Biotechnology reported September grants of inducement awards as required by Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 08, 2020
Puma Biotechnology CEO Alan Auerbach will provide a company overview at the virtual H.C. Wainwright Global Conference on September 15, 2020.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2020
Puma Biotechnology reported the Aug. 2020 issuance of inducement Awards as required by Nasdaq Listing Rule 5635(c)(4).
Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer
September 03, 2020
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
August 19, 2020
A manuscript including results from Puma Biotechnology's CONTROL trial was published in the September 2020 issue of Annals of Oncology.
On August 10, 2020, Puma Biotechnology reported the approval of inducement awards under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology Reports Second Quarter 2020 Financial Results
August 06, 2020
On Aug. 6, 2020, Puma Biotechnology released its financial results for the third quarter and six months ended June 30, 2020.
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
July 27, 2020
Puma Biotechnology's P 2 SUMMIT trial results of neratinib in HER2-Mutant, metastatic cervical cancers were published online in Gynecologic Oncology.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
July 23, 2020
Puma Biotechnology will release its financial results and host a conference call after the close of U.S. markets on August 6, 2020.
Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx® (neratinib) to Health Systems and Hospitals in the Acentrus Network
July 21, 2020
Acentrus Specialty finalizes an agreement with Puma Biotechnology, Inc. to provide qualified Acentrus clients access to NERLYNX® (neratinib).
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cance
July 16, 2020
Puma Biotechnology's licensing partner Specialised Therapeutics Asia received authorization to market NERLYNX in Malaysia.
The Comp Committee of Puma’s Board of Directors approved the grant of 24,500 inducement restricted stock unit awards to 6 new non-executive employees
Puma Biotechnology reports inducement awards for the month of May granted under Nasdaq Listing Rule 5635(c)(4).
On May 8, 2020, Puma Biotechnology reported inducement restricted stock unit awards granted in April 2020 under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology released its financial results for the first quarter ended March 31, 2020 on May 7, 2020.
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breas
May 07, 2020
Puma Biotechnology's licensing partner CANbridge Pharmaceuticals has received regulatory approval to market NERLYNX (neratinib) in Mainland China.
Alan Auerbach, CEO of Puma Biotechnology, will present a corporate update at the BofA Securities Virtual 2020 Health Care Conference on May 13, 2020.
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
April 30, 2020
Puma Biotechnology and Bixink Therapeutics have signed a license agreement in which Bixink will commercialize Puma's drug NERLYNX in South Korea.
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
April 23, 2020
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 7, 2020, following the release of its first quarter...
On March 25, 2020, Puma Biotechnology reported an inducement award granted to Jeff Ludwig as part of his agreement to enter into employment with Puma.
On March 5, Puma Biotechnology reported its February 2020 inducement awards under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
February 28, 2020
On March 4, 2020, Alan Auerbach, CEO and President of Puma Biotechnology, will present a company overview at Cowen's Annual Health Care Conference.
Tags Featured News
From PR Newswire
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
February 26, 2020
Puma Biotechnology has received approval from the U.S. FDA for neratinib (NERLYNX) to treat HER2-positive metastatic breast cancer.